{
    "eid": "2-s2.0-85103572259",
    "title": "Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis",
    "cover-date": "2022-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Nephrology",
            "@code": "2727",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Urology",
            "@code": "2748",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Calcimimetics",
        "FGF23",
        "Fibroblast growth factor 23",
        "Parathyroidectomy",
        "Phosphate binder"
    ],
    "authors": [
        "Kullaya Takkavatakarn",
        "Thunyatorn Wuttiputhanun",
        "Jeerath Phannajit",
        "Kearkiat Praditpornsilpa",
        "Somchai Eiam-Ong",
        "Paweena Susantitaphong"
    ],
    "citedby-count": 3,
    "ref-count": 72,
    "ref-list": [
        "FGF23, biomarker or target?",
        "Klotho converts canonical FGF receptor into a specific receptor for FGF23",
        "Renal and extrarenal effects of fibroblast growth factor 23",
        "FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis",
        "Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease",
        "Plasma fibroblast growth factor 23: clinical correlates and association with cardiovascular disease and mortality in the Framingham heart study",
        "Change in FGF23 concentration over time and its association with all-cause mortality in patients treated with haemodialysis or haemodiafiltration",
        "Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients",
        "Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease",
        "Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community",
        "Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease",
        "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration",
        "Assessing the quality of randomized trials: reliability of the Jadad scale",
        "Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses",
        "Assessing heterogeneity in meta-analysis: Q statistic or I2index?",
        "Bias in meta-analysis detected by a simple, graphical test",
        "Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease",
        "Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD",
        "Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial",
        "Early control of PTH and FGF23 in normophosphatemic ckd patients: a new target in CKD-MBD therapy?",
        "Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate",
        "Effects of phosphate binders in moderate CKD",
        "Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial",
        "Cardiovascular effects of sevelamer in stage 3 CKD",
        "A comparison of calcium acetate/magnesium carbonate and sevelamer\u2013hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study",
        "Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum K lotho levels in chronic haemodialysis patients",
        "Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial",
        "Randomized clinical trial of sevelamer carbonate on serum K lotho and fibroblast growth factor 23 in CKD",
        "Effects of sevelamer carbonate in patients with CKD and proteinuria: the answer randomized trial",
        "Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study",
        "Lanthanum carbonate modulates inflammatory profile in hemodialysis patients: relationship with fibroblast growth factor-23",
        "Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease",
        "The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients",
        "Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the prefect study, a phase 2a, double blind, randomized, placebo-controlled trial",
        "Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients",
        "Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the combine trial",
        "Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD",
        "A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3\u20135",
        "Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial",
        "Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients",
        "Effect of sucroferric oxyhydroxide on fibroblast growth factor 23 levels in hemodialysis patients",
        "A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD",
        "Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients",
        "Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial",
        "Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism",
        "A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients",
        "Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis",
        "Phase 2b study of evocalcet (khk7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: a randomized, double-blind, placebo-controlled, dose-finding study",
        "Impact of parathyroidectomy on serum FGF23 and soluble K lotho in hemodialysis patients with severe secondary hyperparathyroidism",
        "Changes in serum concentrations of fibroblast growth factor 23 and soluble K lotho in hemodialysis patients after total parathyroidectomy",
        "Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis",
        "High-flux hemodialysis benefits hemodialysis patients by reducing serum FGF-23 levels and reducing vascular calcification",
        "Effect of high-flux dialysis on circulating FGF-23 levels in end-stage renal disease patients: results from a randomized trial",
        "Effects of high-flux hemodialysis on FGF-23 and micro-inflammatory state in end-stage renal diseases patients",
        "Effect of high-flux hemodialysis on FGF23 level, calcium\u2013phosphate metabolism disorder, arteriosclerosis, and cardiac function in patients with end-stage renal disease",
        "Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients",
        "Significance of residual renal function for phosphate control in chronic hemodialysis patients",
        "Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice",
        "Effects of dietary phosphate and calcium intake on fibroblast growth factor-23",
        "Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis",
        "Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease",
        "Acute effects of very-low-protein diet on FGF23 levels: a randomized study",
        "Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study",
        "Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial",
        "Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production",
        "Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD",
        "Is fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review",
        "Calcimimetics, mechanisms of action and therapeutic applications",
        "The calcium-sensing receptor and calcimimetics in blood pressure modulation",
        "Cinacalcet for treatment of chronic kidney disease-mineral and bone disorder: a meta-analysis of randomized controlled trials",
        "Fibroblast growth factor 23 in patients undergoing peritoneal dialysis"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60002620",
        "affilname": "Faculty of Medicine, Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
        "affiliation-country": "Thailand"
    },
    "funding": []
}